SS-31 (Elamipretide): Targeting Mitochondrial Dysfunction

SS-31 is a synthetic tetrapeptide that concentrates at the inner mitochondrial membrane. It belongs to the Szeto-Schiller (SS) peptide family developed by Hazel Szeto and Peter Schiller, and it has also been known as MTP-131 and Bendavia; its international nonproprietary name is elamipretide [1]. Rather than acting as a general antioxidant spread through the cell, SS-31 works at the membrane where the electron transport chain sits, through its interaction with the phospholipid cardiolipin [1][2]. This guide covers its structure and mechanism, what each line of evidence shows and in which model, where clinical translation has and has not held up, and how researchers typically study it.

One regulatory fact is worth stating clearly. In September 2025 the U.S. FDA granted accelerated approval to elamipretide, marketed as Forzinity by Stealth BioTherapeutics, for Barth syndrome. The SS-31 sold by Northbridge Research Labs is a research-grade material for laboratory use. It is not Forzinity, and it is not a pharmaceutical product.

Structure

SS-31 has the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine. The motif alternates aromatic and basic residues, giving a small molecule (about 640 Da) that carries three positive charges at physiological pH. The dimethyltyrosine supplies the peptide's radical-scavenging capacity: in the founding 2004 study, analogs lacking Dmt failed to reduce mitochondrial ROS or swelling and did not protect the heart [3]. The D-amino acid at the N-terminus and the C-terminal amide help the peptide resist proteolysis.

SS peptides are cell-permeable and were reported to concentrate about 1,000-fold in the inner mitochondrial membrane [3]. Szeto's group has described this uptake as not relying on the mitochondrial membrane potential, which distinguishes it from lipophilic cation carriers and means depolarized mitochondria can still take it up [1].

Mechanism: Cardiolipin and Cytochrome c

Cardiolipin is an anionic phospholipid found only in the inner mitochondrial membrane. It shapes the cristae and helps organize respiratory complexes into supercomplexes [1]. It also governs cytochrome c: when cytochrome c binds cardiolipin through hydrophobic interactions, it can switch from an electron carrier into a peroxidase that oxidizes cardiolipin itself, damaging the membrane and slowing electron flow [5].

• Using a fluorescent analog, SS-31 was shown to bind cardiolipin with high affinity (biophysical and rat studies) [2].
• In model membranes, SS-31 interacted only with liposomes and bicelles that contained cardiolipin, at roughly a 1:1 ratio, and NMR showed its aromatic residues penetrating deep into the bilayer [5].
• The SS-31/cardiolipin complex inhibited cytochrome c peroxidase activity while preserving cytochrome c's electron-carrying function [2][5].
• In freshly isolated mitochondria, SS-31 increased state 3 respiration and the efficiency of ATP synthesis [5].

A broader picture of the mechanism

Two 2020 studies refined this model. Biophysical and computational work found that SS-31 partitions into the membrane interface with an affinity tied to surface charge, does not destabilize bilayers, and modulates the surface electrostatics of both model and mitochondrial membranes, including the distribution of calcium at the interface [6]. That suggests part of its effect may come from tuning the membrane surface generally rather than from cardiolipin binding alone. A cross-linking mass spectrometry study then mapped SS-31's protein partners in mitochondria: all were known cardiolipin-binding proteins, falling into oxidative phosphorylation and 2-oxoglutarate metabolism groups [7].

Preclinical Evidence, Model by Model

Isolated mitochondria, cells and the ex vivo heart

In neuronal cells, SS peptides reduced intracellular ROS and cell death caused by an oxidant. In isolated mitochondria they lowered ROS production, inhibited the mitochondrial permeability transition and swelling, and prevented calcium-induced cytochrome c release. In an ex vivo heart model they improved contractile force after ischemia [3].

Renal ischemia in rats

Ischemia destroys cristae and delays ATP recovery on reperfusion. In rats given SS-31 before renal ischemia, cristae membranes were protected, mitochondrial swelling was prevented, ATP recovered promptly, and tubular barrier function and kidney function were better preserved [2].

Aged mouse muscle and heart

In 27-month-old mice, a single exposure to SS-31 restored in vivo skeletal muscle mitochondrial energetics (maximal ATP production, coupling and PCr/ATP) to young levels within an hour, with no observable effect in young muscle; eight days of exposure increased whole-animal endurance [4]. An eight-week study in aged female mice reversed the decline in maximal ATP production and coupling, restored redox balance across the muscle proteome and improved treadmill endurance. Notably, mitochondrial protein content did not rise, which points to better function of existing mitochondria rather than more of them [8]. In old mouse hearts, eight weeks of SS-31 substantially reversed diastolic dysfunction, normalized proton leak and lowered mitochondrial ROS; SS-31 gave no further benefit in mice expressing mitochondria-targeted catalase, implicating reduced mitochondrial oxidative stress as a shared mechanism [9].

Clinical Studies: Where Translation Has and Has Not Held

The human trial record is mixed, and a researcher reading the animal literature should know it. These are findings of specific trials in specific patient groups:

• Heart attack reperfusion: in the EMBRACE STEMI phase 2a trial, the compound (as MTP-131) was not associated with a reduction in infarct size, nor with improvement on imaging, angiographic, electrocardiographic or clinical outcomes [10], despite strong ischemia-reperfusion results in animals.
• Primary mitochondrial myopathy: the phase 3 MMPOWER-3 trial, with 218 participants, did not meet its primary endpoints of six-minute walk distance and fatigue score [11].
• Barth syndrome: in a 12-person crossover trial, neither primary endpoint was met in the placebo-controlled part; in the open-label extension, participants reaching 36 weeks showed improvements in six-minute walk distance and a symptom scale [12]. Barth syndrome is itself a disorder of cardiolipin metabolism, which makes it the most mechanistically direct test of the cardiolipin hypothesis.

Open Questions

• Specificity. How much of SS-31's activity comes from selective cardiolipin binding and how much from broader effects on membrane surface charge is still being worked out [6][7].
• The translational gap. Why robust protection in animal ischemia models did not carry over to reperfusion in patients remains unresolved [10].
• Who did the work. Much of the foundational research comes from Szeto and close collaborators. Szeto is the inventor of the SS peptides and founded Stealth BioTherapeutics, and discloses a financial interest in the company [6]. Independent replication is correspondingly valuable.

How Researchers Typically Study It

Isolated-mitochondria and cell studies usually combine high-resolution respirometry (state 3 and state 4 respiration, coupling), ROS or hydrogen peroxide emission, membrane potential dyes, calcium retention and swelling assays for the permeability transition, and cytochrome c peroxidase activity [3][5]. Lipidomics can track cardiolipin oxidation and remodeling. In animals, the Marcinek and Rabinovitch groups have measured muscle energetics in vivo with 31P magnetic resonance and optical spectroscopy [4][8], and cardiac function by echocardiography [9].

Two controls from the literature are worth copying: an analog lacking dimethyltyrosine, which separates scavenging from membrane targeting [3], and a comparison with mitochondria-targeted catalase, which tests whether an effect runs through mitochondrial oxidative stress [9]. Including young animals or healthy cells as a reference is also informative, since several studies saw effects only in aged or stressed mitochondria [4].

Handling and Storage

SS-31 (C32H49N9O5, 639.79 Da) is water-soluble and strongly basic, so at low concentrations it can adsorb to glass and negatively charged surfaces; low-binding plastics help keep working solutions at their nominal concentration. Store the lyophilized powder at -20 °C, sealed and dry, and let the vial reach room temperature before opening. Dissolve it in sterile water or your assay buffer, freeze single-use aliquots, and avoid repeated freezing and thawing. Synthetic peptides are supplied as salts, and the counter-ion can matter in sensitive cell assays, so note it from the certificate when planning controls.

Northbridge Research Labs sends every batch for independent third-party testing. Where a lot's certificate has been published, it is on our COA page; certificates are posted online and are not printed in the box.